Orion Pharma partners with Qilu to commercialize pembrolizumab biosimilar in Europe

Bitget2026/10/06 06:00

Orion Pharma signed an agreement with Qilu Pharma Europe to commercialize an intravenous pembrolizumab biosimilar in Europe. Orion will hold exclusive rights to distribute, market, and sell the product across Europe. Qilu will supply the biosimilar, receive a profit share, and earn development, regulatory, and sales milestone payments. Qilu is currently developing the intravenous pembrolizumab biosimilar. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orion Oyj published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060200OMX_____CNEWS_EN_GNW1001276357_en) on October 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.